Main menu button

News

Equity research CDON: Preview Q3 2025, positive trend confirmed
03 Oct 2025
Equity research CDON: Preview Q3 2025, positive trend confirmed
Equity Research CDON
Equity research White Pearl Technology Group: Upgraded revenue guidance supports the investment case
30 Sep 2025
Equity research White Pearl Technology Group: Upgraded revenue guidance supports the investment case
Equity Research White Pearl Technology Group
Equity research Immunovia: PancreaSure launch in the US is underway
26 Sep 2025
Equity research Immunovia: PancreaSure launch in the US is underway
Equity Research Immunovia
Equity research Viva Wine Group: Process to transfer to the Main list initiated
24 Sep 2025
Equity research Viva Wine Group: Process to transfer to the Main list initiated
Equity Research Viva Wine Group
Equity research CDON: Moderate capital raise, profitability improving in Q3
19 Sep 2025
Equity research CDON: Moderate capital raise, profitability improving in Q3
Equity Research CDON
Equity Research Biosergen: Candidozyma auris on the rise in Europe
17 Sep 2025
Equity Research Biosergen: Candidozyma auris on the rise in Europe
Equity Research Biosergen
Equity Research Svenska Aerogel, Q2 2025: Increasing pipeline supports positive outlook
11 Sep 2025
Equity Research Svenska Aerogel, Q2 2025: Increasing pipeline supports positive outlook
Equity Research Svenska Aerogel
Equity research Candles Scandinavia: Expansion to spark growth and shareholder value
11 Sep 2025
Equity research Candles Scandinavia: Expansion to spark growth and shareholder value
Equity Research Candles Scandinavia
Equity Research ALM Equity: New CEO and incentive programme
10 Sep 2025
Equity Research ALM Equity: New CEO and incentive programme
Equity Research ALM Equity
Video interview, White Pearl Technology Group: The founder’s take on the company, the market and outlook
04 Sep 2025
Video interview, White Pearl Technology Group: The founder’s take on the company, the market and outlook
Equity Research White Pearl Technology Group
Research update Biosergen: Ongoing development going according to plan
02 Sep 2025
Research update Biosergen: Ongoing development going according to plan
Equity Research Biosergen
Equity Research Enrad, Q2 2025: Investments and growth according to plan
02 Sep 2025
Equity Research Enrad, Q2 2025: Investments and growth according to plan
Equity Research Enrad
Equity research Zinzino Q2 2025: Subscribing to rapid growth
02 Sep 2025
Equity research Zinzino Q2 2025: Subscribing to rapid growth
Equity Research Zinzino
Equity research Zinzino Q2 2025: Video interview with CEO Dag Bergheim Pettersen
01 Sep 2025
Equity research Zinzino Q2 2025: Video interview with CEO Dag Bergheim Pettersen
Equity Research Zinzino
Equity research Viva Wine Group, Q2 2025: Soft markets, but expansion is underway
01 Sep 2025
Equity research Viva Wine Group, Q2 2025: Soft markets, but expansion is underway
Equity Research Viva Wine Group
Equity research Zinzino Q2, 2025: Expansion costs hamper margins, but strong outlook
29 Aug 2025
Equity research Zinzino Q2, 2025: Expansion costs hamper margins, but strong outlook
Equity Research Zinzino
Equity research Immunovia: Eventful Q2 and rights issue to support PancreaSure launch
28 Aug 2025
Equity research Immunovia: Eventful Q2 and rights issue to support PancreaSure launch
Equity Research Immunovia
Equity Research Svenska Aerogel, Q2 2025: Strong growth, but lower than expected revenues
28 Aug 2025
Equity Research Svenska Aerogel, Q2 2025: Strong growth, but lower than expected revenues
Equity Research Svenska Aerogel
Equity research Viva Wine Group Q2, 2025: Stable performance in a soft market
28 Aug 2025
Equity research Viva Wine Group Q2, 2025: Stable performance in a soft market
Equity Research Viva Wine Group
Equity research Nosa Plugs Q2, 2025: Growth ahead but mixed results in Q2
27 Aug 2025
Equity research Nosa Plugs Q2, 2025: Growth ahead but mixed results in Q2
Equity Research Nosa Plugs